Contents

Search

Heart & Estrogen/Progestin Replacement Study (HERS)

Study characteristics: - randomized, double-blind, placebo controlled secondary prevention trial - 2763 women, average age 67 years - conjugated equine estrogen 0.625 mg + medroxyprogesterone 2.5 mg QD - mean duration of follow-up 4.2 years - intention to treat analyses Results: 1) hormone replacement therapy (HRT) did not prevent myocardial infarction fatal or otherwise during a 4 year follow-up 2) risk of myocardial infarction acutally increased with HRT during the 1st year 3) no evidence that treatment reduced the incidence of fractures or height loss 4) reduced risk of developing diabetes mellitus (6% vs 10% over period of 4 years) [5]

Related

hormone replacement therapy (HRT); estrogen replacement therapy; postmenopausal hormone replacement therapy

General

clinical trial

References

  1. Greenwood G. In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  2. Cauley JA et al, Am J Med 110:442, 2001
  3. Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
  4. Journal Watch 23(3):28, 2003 Barnabei VM et al, Obstet Gynecol 100:1209, 2002
  5. Journal Watch 23(4):34, 2003 Kanaya AM et al, Ann Intern Med 138:1, 2003